Proto Axiom — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPSV Health InvestorsTenmileAbingworthAlly Bridge Group+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.